Allergen Immunotherapy in the Age of Coronavirus: A Review of Practice Considerations and Evidence to Deliver Uninterrupted Care Evaluation (ID: i775a)

Question Title

* 1. What is your degree?

MD/DO

Other (please specify)

Question Title

* 2. How many years have you been in practice?

>21

11-20

1-10

Question Title

* 3. How many patients receiving allergen immunotherapy do you manage?

1 to 25

26 to 50

51 to 100

100+

I am not directly involved in patient care

Question Title

* 4. Please select the option that best describes your practice setting:

Academic medical center

Community hospital or medical center

Private practice

Managed Care

Research

Pharmaceutical industry

Other (please specify)

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make change

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 7. What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Constant changing guidelines

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Other (please specify)

Question Title

* 8. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Integrate current COVID-19 protocols, AIT management strategies, and patient communication approaches to ensure optimal outcomes for patients on AIT	Integrate current COVID-19 protocols, AIT management strategies, and patient communication approaches to ensure optimal outcomes for patients on AIT Strongly agree	Integrate current COVID-19 protocols, AIT management strategies, and patient communication approaches to ensure optimal outcomes for patients on AIT Agree	Integrate current COVID-19 protocols, AIT management strategies, and patient communication approaches to ensure optimal outcomes for patients on AIT Neutral	Integrate current COVID-19 protocols, AIT management strategies, and patient communication approaches to ensure optimal outcomes for patients on AIT Disagree	Integrate current COVID-19 protocols, AIT management strategies, and patient communication approaches to ensure optimal outcomes for patients on AIT Strongly disagree
Review recent safety and efficacy outcomes from clinical trials involving AIT	Review recent safety and efficacy outcomes from clinical trials involving AIT Strongly agree	Review recent safety and efficacy outcomes from clinical trials involving AIT Agree	Review recent safety and efficacy outcomes from clinical trials involving AIT Neutral	Review recent safety and efficacy outcomes from clinical trials involving AIT Disagree	Review recent safety and efficacy outcomes from clinical trials involving AIT Strongly disagree
Describe the impact of COVID-19 on research and guidance from the FDA to address the evolving demands of clinical trials during the pandemic	Describe the impact of COVID-19 on research and guidance from the FDA to address the evolving demands of clinical trials during the pandemic Strongly agree	Describe the impact of COVID-19 on research and guidance from the FDA to address the evolving demands of clinical trials during the pandemic Agree	Describe the impact of COVID-19 on research and guidance from the FDA to address the evolving demands of clinical trials during the pandemic Neutral	Describe the impact of COVID-19 on research and guidance from the FDA to address the evolving demands of clinical trials during the pandemic Disagree	Describe the impact of COVID-19 on research and guidance from the FDA to address the evolving demands of clinical trials during the pandemic Strongly disagree

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

David Bernstein, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Lawrence DuBuske, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Russell Settipane, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 13. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
I will make changes to my AIT practice as a result of participating in this activity	I will make changes to my AIT practice as a result of participating in this activity Strongly agree	I will make changes to my AIT practice as a result of participating in this activity Agree	I will make changes to my AIT practice as a result of participating in this activity Neutral	I will make changes to my AIT practice as a result of participating in this activity Disagree	I will make changes to my AIT practice as a result of participating in this activity Strongly disagree
I am confident in my ability to implement protocols, AIT management strategies, and communication approaches to ensure optimal outcomes for patients receiving AIT in my practice	I am confident in my ability to implement protocols, AIT management strategies, and communication approaches to ensure optimal outcomes for patients receiving AIT in my practice Strongly agree	I am confident in my ability to implement protocols, AIT management strategies, and communication approaches to ensure optimal outcomes for patients receiving AIT in my practice Agree	I am confident in my ability to implement protocols, AIT management strategies, and communication approaches to ensure optimal outcomes for patients receiving AIT in my practice Neutral	I am confident in my ability to implement protocols, AIT management strategies, and communication approaches to ensure optimal outcomes for patients receiving AIT in my practice Disagree	I am confident in my ability to implement protocols, AIT management strategies, and communication approaches to ensure optimal outcomes for patients receiving AIT in my practice Strongly disagree
I am confident in my knowledge of recent safety and efficacy outcomes data from clinical trials involving AIT	I am confident in my knowledge of recent safety and efficacy outcomes data from clinical trials involving AIT Strongly agree	I am confident in my knowledge of recent safety and efficacy outcomes data from clinical trials involving AIT Agree	I am confident in my knowledge of recent safety and efficacy outcomes data from clinical trials involving AIT Neutral	I am confident in my knowledge of recent safety and efficacy outcomes data from clinical trials involving AIT Disagree	I am confident in my knowledge of recent safety and efficacy outcomes data from clinical trials involving AIT Strongly disagree

Question Title

* 14. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 15. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 16. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 17. Request for Credit

Name

Organization

Degree

Specialty

Address

City, State

ZIP/Postal Code

Telephone

Email Address

Question Title

* 1. What is your degree?

Question Title

* 2. How many years have you been in practice?

Question Title

* 3. How many patients receiving allergen immunotherapy do you manage?

Question Title

* 4. Please select the option that best describes your practice setting:

Question Title

* 5. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 6. Which of the following best describes the impact of this activity on your performance?

Question Title

* 7. What barriers do you see to making changes in your practice?

Question Title

* 8. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree After participating in today’s activity, I am now able to:

Question Title

* 9. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree David Bernstein, MD, effectively:

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree Lawrence DuBuske, MD, effectively:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree Russell Settipane, MD, effectively:

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree The content presented:

Question Title

* 13. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Question Title

* 14. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 15. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related disease state:

Question Title

* 16. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 17. Request for Credit

* 8. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

After participating in today’s activity, I am now able to:

* 9. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

David Bernstein, MD, effectively:

* 10. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Lawrence DuBuske, MD, effectively:

* 11. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

Russell Settipane, MD, effectively:

* 12. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree

The content presented:

* 13. Please rate your level of agreement by checking the appropriate rating.
5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree